TC Home

The only technical publication dedicated to readers who formulate, manufacture, or package solid dosage forms.

Slide background
Slide background
Slide background
  • June 25, 2019

SILVER SPRINGS, MD—The FDA approved Ruzurgi (amifampridine) as the first and only pediatric treatment (ages 6 to 17) of Lambert-Eaton myasthenic syndrome (LEMS), a rare autoimmune disorder that affects the connection between nerves and muscles. It is manufactured by Jacobus Pharmaceutical, Princeton, NJ.